Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases.

Salmon M, Luttmann MA, Foley JJ, Buckley PT, Schmidt DB, Burman M, Webb EF, DeHaas CJ, Kotzer CJ, Barrett VJ, Slack RJ, Sarau HM, Palovich MR, Lainé DI, Hay DW, Rumsey WL.

J Pharmacol Exp Ther. 2013 May;345(2):260-70. doi: 10.1124/jpet.112.202051. Epub 2013 Feb 22.

PMID:
23435542
2.

Tyrosine urea muscarinic acetylcholine receptor antagonists: achiral quaternary ammonium groups.

Jin Q, Davis RS, Bullion AM, Jin J, Wang Y, Widdowson KL, Palovich MR, Foley JJ, Schmidt DB, Buckley PT, Webb EF, Salmon M, Belmonte KE, Sarau HM, Busch-Petersen J.

Bioorg Med Chem Lett. 2012 Dec 1;22(23):7087-91. doi: 10.1016/j.bmcl.2012.09.085. Epub 2012 Oct 2.

PMID:
23099092
3.

Design, synthesis and structure-activity relationship of N-substituted tropane muscarinic acetylcholine receptor antagonists.

Lainé DI, Yan H, Xie H, Davis RS, Dufour J, Widdowson KL, Palovich MR, Wan Z, Foley JJ, Schmidt DB, Hunsberger GE, Burman M, Bacon AM, Webb EF, Luttmann MA, Salmon M, Sarau HM, Umbrecht ST, Landis PS, Peck BJ, Busch-Petersen J.

Bioorg Med Chem Lett. 2012 May 1;22(9):3366-9. doi: 10.1016/j.bmcl.2012.02.015. Epub 2012 Feb 15.

PMID:
22460029
4.

Design, synthesis, and structure-activity relationship of tropane muscarinic acetylcholine receptor antagonists.

Lainé DI, Wan Z, Yan H, Zhu C, Xie H, Fu W, Busch-Petersen J, Neipp C, Davis R, Widdowson KL, Blaney FE, Foley J, Bacon AM, Webb EF, Luttmann MA, Burman M, Sarau HM, Salmon M, Palovich MR, Belmonte K.

J Med Chem. 2009 Aug 27;52(16):5241-52. doi: 10.1021/jm900736e.

PMID:
19630384
5.

Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD.

Wan Z, Laine DI, Yan H, Zhu C, Widdowson KL, Buckley PT, Burman M, Foley JJ, Sarau HM, Schmidt DB, Webb EF, Belmonte KE, Palovich M.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4560-2. doi: 10.1016/j.bmcl.2009.07.006. Epub 2009 Jul 8.

PMID:
19616944
6.

Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists.

Lainé DI, McCleland B, Thomas S, Neipp C, Underwood B, Dufour J, Widdowson KL, Palovich MR, Blaney FE, Foley JJ, Webb EF, Luttmann MA, Burman M, Belmonte K, Salmon M.

J Med Chem. 2009 Apr 23;52(8):2493-505. doi: 10.1021/jm801601v.

PMID:
19317446
7.

Discovery of biphenyl piperazines as novel and long acting muscarinic acetylcholine receptor antagonists.

Jin J, Budzik B, Wang Y, Shi D, Wang F, Xie H, Wan Z, Zhu C, Foley JJ, Webb EF, Berlanga M, Burman M, Sarau HM, Morrow DM, Moore ML, Rivero RA, Palovich M, Salmon M, Belmonte KE, Lainé DI.

J Med Chem. 2008 Oct 9;51(19):5915-8. doi: 10.1021/jm800935u. Epub 2008 Sep 18.

PMID:
18798607
8.

Discovery of novel and long acting muscarinic acetylcholine receptor antagonists.

Jin J, Wang Y, Shi D, Wang F, Davis RS, Jin Q, Fu W, Foley JJ, Webb EF, Dehaas CJ, Berlanga M, Burman M, Sarau HM, Morrow DM, Rao P, Kallal LA, Moore ML, Rivero RA, Palovich M, Salmon M, Belmonte KE, Busch-Petersen J.

J Med Chem. 2008 Aug 28;51(16):4866-9. doi: 10.1021/jm800634k. Epub 2008 Aug 5.

PMID:
18680280
9.

Discovery of novel 8-azoniabicyclo[3.2.1]octane carbamates as muscarinic acetylcholine receptor antagonists.

Lainé DI, Xie H, Buffet N, Foley JJ, Buckley P, Webb EF, Widdowson KL, Palovich MR, Belmonte KE.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6066-9. Epub 2007 Sep 25.

PMID:
17911022
10.

Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity.

Adams JL, Boehm JC, Gallagher TF, Kassis S, Webb EF, Hall R, Sorenson M, Garigipati R, Griswold DE, Lee JC.

Bioorg Med Chem Lett. 2001 Nov 5;11(21):2867-70.

PMID:
11597418
11.

SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.

Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, Griswold DE.

Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L895-902.

12.

Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.

Sarau HM, Griswold DE, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Webb EF, Martin LD, Legos JJ, Whitmore RG, Barone FC, Medhurst AD, Luttmann MA, Giardina GA, Hay DW.

J Pharmacol Exp Ther. 2000 Oct;295(1):373-81.

PMID:
10992004
13.

SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.

Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE.

J Pharmacol Exp Ther. 2000 Apr;293(1):281-8.

PMID:
10734180
14.
15.

In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity.

Sarau HM, Foley JJ, Schmidt DB, Martin LD, Webb EF, Tzimas MN, Breton JJ, Chabot-Fletcher M, Underwood DC, Hay DW, Kingsbury WD, Chambers PA, Pendrak I, Jakas DR, Sathe GM, Van Horn S, Daines RA, Griswold DE.

Prostaglandins Leukot Essent Fatty Acids. 1999 Jul;61(1):55-64.

PMID:
10477044
16.

Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.

Adams JL, Boehm JC, Kassis S, Gorycki PD, Webb EF, Hall R, Sorenson M, Lee JC, Ayrton A, Griswold DE, Gallagher TF.

Bioorg Med Chem Lett. 1998 Nov 17;8(22):3111-6.

PMID:
9873686
17.

SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.

Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, Grous M, Christensen S, Torphy TJ.

J Pharmacol Exp Ther. 1998 Nov;287(2):705-11.

PMID:
9808700
18.
19.

Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.

Sarau HM, Griswold DE, Potts W, Foley JJ, Schmidt DB, Webb EF, Martin LD, Brawner ME, Elshourbagy NA, Medhurst AD, Giardina GA, Hay DW.

J Pharmacol Exp Ther. 1997 Jun;281(3):1303-11.

PMID:
9190866
20.

Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.

Adams JL, Garigipati RS, Sorenson M, Schmidt SJ, Brian WR, Newton JF, Tyrrell KA, Garver E, Yodis LA, Chabot-Fletcher M, Tzimas M, Webb EF, Breton JJ, Griswold DE.

J Med Chem. 1996 Dec 20;39(26):5035-46.

PMID:
8978834
21.

Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responses.

Reddy MP, Webb EF, Cassatt D, Maley D, Lee JC, Griswold DE, Truneh A.

Int J Immunopharmacol. 1994 Oct;16(10):795-804.

PMID:
7843851
22.

Effects of scalaradial, a type II phospholipase A2 inhibitor, on human neutrophil arachidonic acid mobilization and lipid mediator formation.

Marshall LA, Winkler JD, Griswold DE, Bolognese B, Roshak A, Sung CM, Webb EF, Jacobs R.

J Pharmacol Exp Ther. 1994 Feb;268(2):709-17.

PMID:
8113982
23.

Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response.

Griswold DE, Webb EF, Breton J, White JR, Marshall PJ, Torphy TJ.

Inflammation. 1993 Jun;17(3):333-44.

PMID:
7687237
24.

Beneficial effects of SK&F 105685 in rat adjuvant arthritis: prophylactic and therapeutic effects on disease parameter progression.

Badger AM, Swift BA, Webb EF, Clark RK, Bugelski PJ, Griswold DE.

Int J Immunopharmacol. 1993 Apr;15(3):343-52.

PMID:
8505147
25.

Pharmacology of the pyrroloimidazole, SK&F 105809--II. Antiinflammatory activity and inhibition of mediator production in vivo.

Griswold DE, Marshall PJ, Lee JC, Webb EF, Hillegass LM, Wartell J, Newton J Jr, Hanna N.

Biochem Pharmacol. 1991 Jul 25;42(4):825-31.

PMID:
1907825
26.

Pharmacology of the pyrroloimidazole, SK&F 105809--I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.

Marshall PJ, Griswold DE, Breton J, Webb EF, Hillegass LM, Sarau HM, Newton J Jr, Lee JC, Bender PE, Hanna N.

Biochem Pharmacol. 1991 Jul 25;42(4):813-24.

PMID:
1907824
27.
28.

Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism.

Griswold DE, Marshall P, Martin L, Webb EF, Zabko-Potapovich B.

Agents Actions Suppl. 1991;32:113-7.

PMID:
1906235
29.

Inhibition of inflammatory cell infiltration by bicyclic imidazoles, SK&F 86002 and SK&F 104493.

Griswold DE, Hoffstein S, Marshall PJ, Webb EF, Hillegass L, Bender PE, Hanna N.

Inflammation. 1989 Dec;13(6):727-39.

PMID:
2559032
30.

SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.

Griswold DE, Marshall PJ, Webb EF, Godfrey R, Newton J Jr, DiMartino MJ, Sarau HM, Gleason JG, Poste G, Hanna N.

Biochem Pharmacol. 1987 Oct 15;36(20):3463-70.

PMID:
2823821
31.

Phlogistic activity of leukotriene D4 in the mouse.

Griswold DE, Webb EF, Clark MA, Mong S.

Inflammation. 1986 Mar;10(1):1-7.

PMID:
3957421
32.

Microprocessor-assisted plethysmograph for the measurement of mouse paw volume.

Webb EF, Griswold DE.

J Pharmacol Methods. 1984 Sep;12(2):149-53.

PMID:
6536818
33.

Inhibition of carrageenan-induced inflammation by urethan anesthesia in adrenalectomized and sham-operated rats.

Griswold DE, Alessi S, Webb EF, Walz DT.

J Pharmacol Methods. 1982 Sep;8(2):161-4. No abstract available.

PMID:
7144211
34.

Continuing education do's and don't's.

Webb EF.

Ala Nurse. 1982 Sep;39(1):7. No abstract available.

PMID:
6923704
35.

ENZYME THERAPY OF DENDRITIC KERATITIS.

WEBB EF.

IMJ Ill Med J. 1965 Feb;127:176-9. No abstract available.

PMID:
14270234
36.

Conjunctival dermoid with marked seborrheic component.

WEBB EF.

AMA Arch Ophthalmol. 1954 Jul;52(1):132-3. No abstract available.

PMID:
13170878

Supplemental Content

Support Center